An observational study in Bone Marrow Failure Syndromes, Erythrocyte Disorder and Leukocyte Disorder, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by St. Jude Children's Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Bone Marrow Failure Disorders with a site in United States — 21 open to participants now, 29 under way, none of them phase 3. Bone Marrow Failure Disorders · United States.
Among the 67 studies in Bone Marrow Failure Disorders with a site in United States, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2016, is one of 10 observational ones, reaches primary completion later than 27 of the 28 other live ones, and was the 31st registered.
91 studies on the registry are indexed under Bone Marrow Failure Disorders; 29 are open to participants now.
Browse Bone Marrow Failure Disorders studies →21 of the 67 studies in Bone Marrow Failure Disorders with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages 18–25
Dren Bio · Sites in United States
Ages 18+
Medical College of Wisconsin · Sites in United States
Healthy volunteers
Nationwide Children's Hospital · Sites in United States
Ages 0–12
Suneet Agarwal · Sites in United States
Ages 1–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Bone Marrow Failure Disorders studies recruiting now, 9 (39%) set no upper age limit and 12 (52%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 37 · Phase 3 3
First in 1986; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,716 is above the median of 350 across 17 observational studies indexed under Bone Marrow Failure Disorders.
Median enrollment 23 across the 55 interventional studies, 325 across the 10 observational. Of the 32 that completed or were terminated, 15 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 67 have an industry lead sponsor. The 10 most frequent:
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
St. Jude Children's Research Hospital has 3 studies filed under Bone Marrow Failure Disorders — fewer than ten, so there is no comparison to draw.
6 of the studies in Bone Marrow Failure Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01659606Boston Children's HospitalRadiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita | 2026-12 |
| NCT04644016Memorial Sloan Kettering Cancer CenterCord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | 2026-12-20 |
| NCT02356653Children's Hospital of PhiladelphiaExpanded Access Protocol Using CD3+/CD19+ Depleted PBSC | 2027-01 |
| NCT03579875Masonic Cancer Center, University of MinnesotaAlpha/Beta TCD HCT in Patients With Inherited BMF Disorders | 2027-01-01 |
| NCT04356469Johns Hopkins All Children's HospitalTCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 67 studies in Bone Marrow Failure Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings, urine, saliva and buccal swabs, left over tissue, as well as health information will be used to study and learn about blood diseases by using genetic and/or genomic research. In general, genetic research studies specific genes of an individual; genomic research studies the complete genetic makeup of an individual.
It is not known why many people have blood diseases, because not all genes causing these diseases have been found. It is also not known why some people with the same disease are sicker than others, but this may be related to their genes. By studying the genomes in individuals with blood diseases and their family members, the investigators hope to learn more about how diseases develop and respond to treatment which may provide new and better ways to diagnose and treat blood diseases.
Primary Objective:
Secondary Objectives:
Exploratory Objectives
Participants will be individuals (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder. We propose to use genomics, transcriptomics, proteomics and metabolomic analysis coupled with family linkage studies to identify causal mutations in individuals with undefined hematologic disorders and to characterize genetic modifiers of defined monogenic blood diseases.
A detailed medical history will be obtained, including demographic information for each proband. For each identified biologically related family member, a medical history questionnaire will be obtained. The family history and pedigree will be reviewed in conjunction with a geneticist/genetic counselor. The implications of genetic testing will be explained. If participants consent for future contact, this will take place annually for updates on medical and family history.
All probands will provide peripheral blood samples, and probands who are undergoing a bone marrow aspirate/biopsy for clinical purposes will provide additional aspirates. Biological family members will provide peripheral blood samples as a source for DNA.
Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
Percent of participants who agree to participate
It is estimated that approximately 30% of participants (proband) approached for this study will agree to participate and that each proband will have approximately five biologically-related family members who agree to participate.
Time frame: Day 1, at enrollment
Number by type of inherited genetic aberrations associated with hematologic disorders
Germ-line DNA samples from study participants will be extracted and analyzed in order to identify inherited genetic aberrations associated with hematologic disorders. Specific modalities of genomic testing will be case specific. Relevant tests may involve SNP arrays to assess copy number variation, WGS, WES, targeted sequencing of specific candidate genes, DNA sequencing, RNA-sequencing, X-chromosome inactivation studies, ChIP sequencing and/or other tests. Genetic linkage analyses may be performed using a variety of technologies including high-density SNP arrays, WGS and specific analysis of selected target genes in validation studies.
Time frame: Blood drawn at study entry, yearly and as needed until July 2050; and/or bone marrow aspirate at study entry, yearly and as needed until July 2050
Number by type of modifier genes
Investigators seek to identify modifier genes in individuals in the study population. Methods of analysis will be similar to those for Outcome Measure #2.
Time frame: Blood drawn at study entry, yearly, and as needed until July 2050; and/or bone marrow aspirate at study entry, yearly and as needed until July 2050.
Number by type of genetic variants
Investigators seek to identify genetic variants associated with treatment outcomes and toxicities in the study population. Methods of analysis will be similar to those for Outcome Measure #2.
Time frame: Blood drawn at study entry, yearly and as needed until July 2050; and/or bone marrow aspirate at study entry, yearly and as needed until July 2050.
Started Jun 2016 (actual). Primary completion is estimated for Jul 2040, 289 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bone Marrow Failure Disorders →
St. Jude Children's Research Hospital →